Exploring WRN Inhibition in MSI Tumors to Expand Synthetic Lethality Strategies Beyond PARP
- See how the MD Anderson Cancer Center are advancing first-in-human trial data for WRN inhibitors in MSI solid tumors
- Interpreting translational relevance and biomarker integration
- Positioning WRN as a synthetic lethality target beyond PARP